Cancer Biomarkers Market, By Biomarker Type (CA 125, HER2, EGFR, CD20, BRAF, Calcitonin, Others), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Kidney Cancer, Liver Cancer, Head & neck Cancer, Non-small Cell Lung Cancer, Other Cancers), By

Cancer Biomarkers Market, By Biomarker Type (CA 125, HER2, EGFR, CD20, BRAF, Calcitonin, Others), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Kidney Cancer, Liver Cancer, Head & neck Cancer, Non-small Cell Lung Cancer, Other Cancers), By Profiling Technology (OMICS Technology, Imaging Technology, Immunoassays, Cytogenetics, Others), By End User (Hospitals, Specialty Clinics, Diagnostic Laboratories, Academic & Research Institutes, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Cancer biomarkers are biological molecules found in blood, tissues or other body fluids that are sign of a normal or abnormal process, or of a condition or disease. These can be used to detect and monitor cancer or cancer progression. In recent years, cancer biomarkers have gained significant attention from both global public and private organizations as these present minimally invasive ways to diagnose, stage and track cancer. Their use also enables oncologists to personalize treatments based on individual patient’s cancer profiles. Advancements in genetic profiling and high-throughput technologies have unlocked the potential of biomarkers that can predict treatment responses and disease progression more accurately. This has promising implications for improving cancer care globally.

Market Dynamics:

Global cancer biomarkers market growth is driven by rising cancer prevalence worldwide, increasing popularity of precision medicine and companion diagnostics, and growing use of biomarkers in drug development as well as approvals. However, high costs associated with biomarker discovery, validation, and commercialization pose a challenge. Moreover, technical limitations and lack of reimbursements restrain the market growth. The market witnesses lucrative opportunities from emerging economies with large cancer populations and growing health expenditures. Further opportunities lie in discovery of novel biomarkers especially for hard-to-treat cancers through ongoing research efforts.

Key Features of the Study:

• This report provides in-depth analysis of the global cancer biomarkers market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global cancer biomarkers market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study includes bioMérieux Inc., INOVIQ, Bio-Rad Laboratories Inc., Abbott, Becton Dickinson and Company, Merck KGaA, QIAGEN N.V., Thermo Fisher Scientific Inc., CENTOGENE N.V., PerkinElmer Inc., Siemens Healthineers, F. Hoffmann-la Roche Ltd, Agilent Technologies, Inc, Invitae Corporation, Myriad Genetics, Guardant Health, Illumina, and FOUNDATION MEDICINE, INC.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global cancer biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer biomarkers market

Detailed Segmentation-

• Biomarker Type:
• CA 125
• HER2
• EGFR
• CD20
• BRAF
• Calcitonin
• Others
• Cancer Type:
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Kidney Cancer
• Liver Cancer
• Head & neck Cancer
• Non-small Cell Lung Cancer
• Other Cancers
• Profiling Technology:
• OMICS Technology
• Imaging Technology
• Immunoassays
• Cytogenetics
• Others
• End User:
• Hospitals
• Specialty Clinics
• Diagnostic Laboratories
• Academic Research Institutes
• Others
• Regional:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• bioMérieux Inc.
• INOVIQ
• Bio-Rad Laboratories Inc.
• Abbott
• Becton Dickinson and Company
• Merck KgaA
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• CENTOGENE N.V.
• PerkinElmer Inc.
• Siemens Healthineers
• Hoffmann-la Roche Ltd
• Agilent Technologies, Inc
• Invitae Corporation
• Myriad Genetics
• Guardant Health
• Illumina
• FOUNDATION MEDICINE, INC.